Processa Pharmaceuticals, Inc. Research and Development in Process
Processa Pharmaceuticals, Inc. (PCSA) reported Research and Development in Process of $566.58 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-30
- Processa Pharmaceuticals, Inc. research and development in process for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. research and development in process for the quarter ending 2021-09-30 was $50.95K, a 97.45% decline year-over-year.
- Processa Pharmaceuticals, Inc. research and development in process for the quarter ending 2021-06-30 was $515.63K.
- Processa Pharmaceuticals, Inc. research and development in process for the quarter ending 2020-12-31 was $6.70M.
- Processa Pharmaceuticals, Inc. research and development in process for fiscal 2021 was $566.58K, a 93.49% decline from fiscal 2020.
- Processa Pharmaceuticals, Inc. research and development in process for fiscal 2020 was $8.70M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $50.95K derived: sum of 2 quarters · filed 2023-03-30 | $566.58K derived: sum of 3 quarters · filed 2023-03-30 | $566.58K 10-K · filed 2023-03-30 |
| 2021-09-30 | $50.95K 10-Q · filed 2022-11-08 | $566.58K derived: sum of 2 quarters · filed 2022-11-08 | $566.58K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $515.63K 10-Q · filed 2022-08-11 | $515.63K 10-Q · filed 2022-08-11 | ||
| 2020-12-31 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $8.70M derived: sum of 2 quarters · filed 2022-03-30 | $8.70M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $2.00M 10-Q · filed 2021-11-12 | $2.00M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |